SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Livzon Pharmaceutical’s Mabpharm Receives NMPA Clinical Trial Approval Notice

Livzon Pharmaceutical said Mabpharm received a drug clinical trial approval notice from China’s NMPA.

SquawkNews Desk 2 updates Updated Oct 27, 2026, 08:49 AM UTC

Story updates

08:49:20 AM UTC
SquawkNews
Livzon-Tochter MABPharm erhält Genehmigung für Phase-I-Studie mit Anti-FXI-Antikörper Livzon MAB
08:49:20 AM UTC
SquawkNews
Livzon Subsidiary MABPharm Wins China Approval for Phase I Trial of Anti-FXI Antibody Livzon Pha

Related stories

Íslandsbanki Reports Third-Quarter 2026 Financial Results Íslandsbanki reported net profit of ISK 7.3 billion for the third quarter of 2026. M impact | EQUITY | Oct 29, 2026, 03:46 PM UTC Cohere Announces Series E Fundraise Targeting CAD $7 Billion Cohere announced a Series E fundraise targeting CAD $7 billion. M impact | EQUITY | Oct 29, 2026, 03:45 PM UTC Forestar Reports Q4 FY26 Net Income of $59.2 Million, Revenue of $580.8 Million M impact | EQUITY | Oct 29, 2026, 03:45 PM UTC Íslandsbanki Reports Third-Quarter 2026 Results Íslandsbanki reported third-quarter 2026 results. M impact | EQUITY | Oct 29, 2026, 03:45 PM UTC Hyatt Hotels Reports Quarterly Results for Quarter Ended September 30 M impact | EQUITY | Oct 29, 2026, 03:45 PM UTC CSW Industrials Reports Quarterly Results for Quarter Ended September 30 M impact | EQUITY | Oct 29, 2026, 03:44 PM UTC